PE20221663A1 - Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano - Google Patents

Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano

Info

Publication number
PE20221663A1
PE20221663A1 PE2022001520A PE2022001520A PE20221663A1 PE 20221663 A1 PE20221663 A1 PE 20221663A1 PE 2022001520 A PE2022001520 A PE 2022001520A PE 2022001520 A PE2022001520 A PE 2022001520A PE 20221663 A1 PE20221663 A1 PE 20221663A1
Authority
PE
Peru
Prior art keywords
composition
proteoglucan
protein
binding protein
lung diseases
Prior art date
Application number
PE2022001520A
Other languages
English (en)
Inventor
Dae Kyong Kim
Yong Wei Piao
Ji Min Jang
Dan Zhou
So Yoon Yun
Bo Kyung Park
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of PE20221663A1 publication Critical patent/PE20221663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UNO SELECCIONADO DEL GRUPO QUE CONSISTE EN PROTEINA HAPLN1 (PROTEINA 1 DE UNION DE HIALURONANO Y PROTEOGLUCANO), UN GEN QUE CODIFICA LA PROTEINA HAPLN1 Y UN AGENTE EFICAZ PARA POTENCIAR LA EXPRESION O ACTIVAR LAS FUNCIONES DE LA PROTEINA O DEL GEN HAPLN1 COMO PRINCIPIO ACTIVO; DONDE LA PROTEINA HAPLN1 COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE TIENE AL MENOS UN 95 % DE IDENTIDAD DE SECUENCIA CON SEQ ID NO: 1. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PULMONARES COMO BRONQUITIS CRONICA, ASMA, ENFISEMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA (EPOC).
PE2022001520A 2020-02-03 2021-02-02 Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano PE20221663A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200012742A KR102166453B1 (ko) 2020-02-03 2020-02-03 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
PCT/KR2021/001374 WO2021158000A1 (en) 2020-02-03 2021-02-02 Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1

Publications (1)

Publication Number Publication Date
PE20221663A1 true PE20221663A1 (es) 2022-10-26

Family

ID=72882981

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001520A PE20221663A1 (es) 2020-02-03 2021-02-02 Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano

Country Status (17)

Country Link
US (1) US20220305077A1 (es)
EP (1) EP3887525B1 (es)
JP (1) JP7329877B2 (es)
KR (1) KR102166453B1 (es)
CN (1) CN115427576A (es)
AR (1) AR121243A1 (es)
AU (1) AU2021216358A1 (es)
BR (1) BR112022015361A2 (es)
CA (1) CA3166146A1 (es)
CL (1) CL2022002067A1 (es)
CO (1) CO2022011135A2 (es)
ES (1) ES2964715T3 (es)
IL (1) IL294952A (es)
MX (1) MX2022009544A (es)
PE (1) PE20221663A1 (es)
TW (1) TWI792171B (es)
WO (1) WO2021158000A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102284800B1 (ko) 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법
KR102678583B1 (ko) * 2021-05-31 2024-06-27 중앙대학교 산학협력단 Hapln1을 포함하는 혈관질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785969B1 (ko) 2004-05-12 2007-12-14 동아제약주식회사 Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
CN104093415B (zh) * 2011-10-24 2017-04-05 哈洛齐梅公司 抗乙酰透明质酸剂疗法的同伴诊断剂及其使用方法
AU2013271392B2 (en) * 2012-06-08 2018-02-15 Ethris Gmbh Pulmonary delivery of mRNA to non-lung target cells
CA2878163A1 (en) * 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
KR101897340B1 (ko) * 2015-09-09 2018-09-13 중앙대학교 산학협력단 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물
CA3055168C (en) * 2017-03-06 2022-09-06 Haplnscience inc. Composition for skin aging measurement, prevention, or alleviation using hapln1

Also Published As

Publication number Publication date
AU2021216358A1 (en) 2022-09-01
ES2964715T3 (es) 2024-04-09
BR112022015361A2 (pt) 2022-09-20
IL294952A (en) 2022-09-01
CL2022002067A1 (es) 2023-01-20
EP3887525B1 (en) 2023-08-23
EP3887525A1 (en) 2021-10-06
JP7329877B2 (ja) 2023-08-21
JP2022524899A (ja) 2022-05-11
EP3887525A4 (en) 2022-06-22
WO2021158000A1 (en) 2021-08-12
CA3166146A1 (en) 2021-08-12
TW202130360A (zh) 2021-08-16
KR102166453B1 (ko) 2020-10-15
EP3887525C0 (en) 2023-08-23
CN115427576A (zh) 2022-12-02
CO2022011135A2 (es) 2022-08-30
MX2022009544A (es) 2022-08-25
TWI792171B (zh) 2023-02-11
AR121243A1 (es) 2022-05-04
US20220305077A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20221663A1 (es) Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano
CL2019003404A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
MX2021015753A (es) Constructo de arn.
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
AR125394A2 (es) Métodos y composiciones para la expresión génica en plantas
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
BR112021019520A2 (pt) Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
HRP20110386T1 (hr) Sintetička sekvenca mecp2 za zamjensku proteinsku terapiju
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
AR101959A1 (es) Composiciones que comprenden células recombinantes de bacillus y un insecticida
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
PE20180509A1 (es) Composiciones y metodos para tratar la enfermedad celiaca
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112016021000A2 (pt) Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf)
BR112022020871A2 (pt) Agentes imunoestimuladores em combinação com inibidores da angiogênese
PE20230487A1 (es) Variantes de alfa-galactosidasa humana
BR112021024997A2 (pt) Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso